Kestra Medical Technologies, Ltd.

Kestra Medical Technologies, Ltd.

KMTS
Kestra Medical Technologies, Ltd.US flagNASDAQ Global Select
24.42
USD
+0.44
- -
1.43BMarket Cap
2020 Y
2021 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
0.38
1.4
2.43
- -
1.75
Basic EPS, GAAP
-1.48
-1.71
-4.36
-5.07
-5.13
- -
-2.43
Free Cash Flow per Basic Share
-1.54
-1.52
-4.28
-4.26
-4.12
- -
-2.16
Dividend per Share
0.01
0.01
0.03
0.04
0.07
- -
0.01
Book Value per Share
-6.84
-8.55
-15.71
-19.44
-19.07
- -
-10.94
Tangible Book Value per Share
0.19
0.09
-5.91
-10.53
8.36
- -
4.79
Basic Weighted Avg Shares
20
20
20
20
25
- -
54
Sales/Revenue/Turnover
- -
- -
8
28
60
95
95
Operating Margin (%)
- -
- -
-1,054.01
-305.83
-177.85
-141.64
-141.65
Depreciation Expense
- -
- -
5
12
8
9
9
Net Income, GAAP
-29
-34
-84
-94
-114
-132
-132
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1,104.04
-338.39
-190.28
-138.36
-138.36
Working Capital
2
20
-18
-18
217
172
172
LT Debt
- -
22
17
45
44
47
47
Total Equity
4
2
-118
-209
205
260
260
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Oct'26
Jan'26
Apr'26
ST Debt
- -
- -
- -
LT Borrowings
42
42
43
LT Finance Leases
3
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
58
58
Market Capitalization
1,210
1,129
1,124

Working Capital

FRC

in mil. unless spec.
Oct'26
Jan'26
Apr'26
Total Current Assets
195
314
222
Cash, Cash Equivalents & STI
175
291
196
Accounts Receivable, Net
10
13
15
Inventories
7
7
7
Total Current Liabilities
36
43
50
Payables & Accruals
27
33
36
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1,381.14%
26.41%
Free Cash Flow
- -
43.06%
15.74%
Net Income, GAAP
- -
42.21%
15.64%
Sales/Revenue/Turnover
- -
- -
59.03%
Total Cash Common Dividend
- -
-174.86%
-103.03%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
10
- -
- -
28
2025
13
15
15
17
60
2026
19
23
25
29
95

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.18
- -
- -
- -
-5.07
2025
-0.45
-1.19
-0.5
-2.25
-5.13
2026
-0.5
-0.64
-0.61
-0.67
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.04
2025
0.02
0.03
- -
- -
0.07
2026
- -
- -
- -
0.01
- -

Company Description

APIChatGPT
CEO
Brian Webster
Full Time Employees
330
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
3933 Lake Washington Blvd NE Kirkland WA United States of America 98033
IPO Date
Mar 6, 2025
Business
Kestra Medical Technologies, Ltd. (KMTS) develops and commercializes wearable medical devices and digital healthcare solutions focused on protecting patients at risk of sudden cardiac arrest through intuitive, intelligent, and connected diagnostic and therapeutic technologies; its core Cardiac Recovery System platform integrates the ASSURE Wearable Cardioverter Defibrillator (WCD) for continuous monitoring and automatic defibrillation of ventricular arrhythmias, the Kestra CareStation cloud-based remote patient data platform for provider oversight and notifications, the ASSURE patient mobile application for self-management, activity tracking, educational content, and data transmission, and the ASSURE Wearable ECG for post-WCD monitoring using the same SensorFit garment and algorithms. Kestra Medical Technologies operates primarily in the cardiovascular disease segment, targeting heart failure patients and those with low left ventricular ejection fraction awaiting therapy eligibility; it serves healthcare providers including over 550 hospitals across the United States with in-network payer coverage reaching 285 million lives, and maintains a presence in Ireland. Founded in 2014 and headquartered in Kirkland, Washington, the company employs approximately 300 people and has grown its clinical registry beyond 20,000 patients. In July 2024, Kestra Medical Technologies completed an oversubscribed $196 million financing round co-led by Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds, with participation from T. Rowe Price Investment Management, Eventide Asset Management, Gilmartin Capital, Bain Capital, and Endeavour Vision, funding commercial expansion of the ASSURE system; in March 2025, it priced an upsized initial public offering on Nasdaq at $17 per share, raising $202 million; fiscal year 2025 delivered record revenue of $59.8 million, up 115% year-over-year, with 3,903 ASSURE prescriptions in Q4 alone (up 43%) and gross margins expanding to 40.5%, alongside commercial team growth to 80 sales territories and FY2026 revenue guidance of $85 million.

Company News

APIChatGPT
  • Kestra Medical Technologies, Ltd. (KMTS) Q4 2026 Earnings Call Transcript

  • Kestra Medical Technologies, Ltd. (KMTS) Reports Q4 Loss, Tops Revenue Estimates

  • Kestra Medical Technologies Q4 Earnings Call Highlights

  • Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

  • Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results

  • Kestra Medical Technologies to Report Fourth Quarter Fiscal 2026 Financial Results on July 14

  • What a $312,000 Kestra Insider Sale Signals After 25% Stock Gains

  • Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares

  • Kestra Medical Technologies, Ltd. (KMTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference

  • Kestra Showcases Accelerated Innovation at HRS 2026

  • Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner

  • The Kestra Director Who Built and Sold a Device Company Keeps Buying Stock

  • Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”

  • Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $304,050.00 in Stock

  • Kestra Medical Technologies, Ltd. (KMTS) Q3 2026 Earnings Call Transcript

  • Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results

  • Kestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17

  • Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares

  • Short Interest in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Rises By 21.5%